A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

As weight loss jabs like Ozempic become ever more popular, doctors are growing increasingly concerned about their gnarly side ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Beyond the kilos: Wegovy’s real benefits One of the most impressive things about Wegovy is that its impact goes far beyond the weighing scale.

Doctors explain why headaches are popular among Wegovy and Ozempic patients and how to treat and prevent them, including ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, Wegovy is a once-weekly injectable using a user-friendly FlexTouch pen.

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

For Wegovy, that was up significantly from 40% who started therapy in 2023 and 34% who began three years ago in this analysis by Prime Therapeutics, a pharmacy benefits manager (PBM). Patrick Gleason, ...

Wegovy (semaglutide) is an FDA-approved medication for chronic weight management. Learn more about Wegovy, including how it works and potential risks.